Evidence map›Paper›PMID 36840495›Full record

ArticleImmunity, inflammation and disease2023

Viral load of SARS-CoV-2 Omicron BA.5 is lower than that of BA.2 despite the higher infectivity of BA.5.

Yuna Takatsuki, Yuta Takahashi, Jun Nakajima, Yumi Iwasaki, Katsutoshi Nagano, Chihiro Tani-Sassa, Sonoka Yuasa, Saki Kanehira, Kazunari Sonobe, Yoko Nukui and 6 more

Open access · goldAbstract read
In one paragraph

Article in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Yuna TakatsukiClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Yuta TakahashiClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Jun NakajimaClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Yumi IwasakiClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Katsutoshi NaganoClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Chihiro Tani-SassaClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Sonoka YuasaClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Saki KanehiraClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Kazunari SonobeClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Yoko NukuiInfection Control and Prevention, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Hiroaki TakeuchiDepartment of Molecular Virology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.ORCID 0000-0002-5689-9858
Kousuke TanimotoGenome Laboratory, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Yukie TanakaDepartment of Molecular Microbiology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Akinori KimuraInstitute of Research, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Naoya IchimuraClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.
Shuji TohdaClinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.ORCID 0000-0002-2642-5459
Tokyo Medical and Dental University Hospital · JPTokyo Medical and Dental University · JP

Funding

Japan Agency for Medical Research and Development 20nk0101612h0901JST-CREST JPMJCR20H2
6 · The paper itself

Abstract

backgroundSublineage BA.5 of the SARS-CoV-2 Omicron variant rapidly spread and replaced BA.2 in July 2022 in Tokyo. A high viral load can be a possible cause of high transmissibility. METHODS AND

resultsThe copy numbers of SARS-CoV-2 in nasopharyngeal swab samples obtained from all patients visiting the hospital where this research was conducted were measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Viral genotypes were determined using PCR-based melting curve analysis. Next, whole-genome sequencing was performed using approximately one fifth of the samples to verify the viral genotypes determined using PCR. Then, the copy numbers of the BA.1, BA.2, and BA.5 cases were compared. Contrary to expectations, the copy numbers of the BA.5 cases (median 4.7 × 10

conclusionThe results presented here suggest that the increased infectivity of BA.5 is not caused by higher viral loads, but presumably by other factors such as increased affinity to human cell receptors or immune escape due to its L452R mutation.

Indexed as

COVID-19GenotypeHumansSARS-CoV-2Viral LoadBA.5COVID-19Omicron variantSARS-CoV-2viral load

Identifiers

PMID36840495
PMCPMC9933202
OpenAlexW4321114208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.